PER-101-03已完成未知
STUDY RANDOMIZED PHASE II, COMBINATION OF ANASTROZOL (NSC 719344) MAS ZD1839 (IRESSA, NSC No. 715055, IND No. 61187) AND THE COMBINATION OF FULVESTRANT (NSC · 719276) MAS ZD1839 IN THE TREATMENT OF POSTMENOPAUS WOMEN WITH CANCER OF METASTASIC MAMA AND POSITIVE HORMONAL RECEPTORS.
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 个研究点目标入组 0 人开始时间: 2004年2月13日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Patients must have estrogen and/or progesterone receptor positive histologically confirmed adenocartinoma of the breast with measurable recurrent or metastatic carcinoma of the breast.
排除标准
- •not contemplated
研究者
相似试验
已完成
2 期
Randomized Phase II Trial of Anastrozole plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast CancerJPRN-UMIN000006434Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine120
进行中（未招募）
不适用
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21postmenopausal women with hormone receptor positive early breast cancerEUCTR2005-005715-22-ATAstraZeneca AB176
进行中（未招募）
1 期
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21EUCTR2005-005715-22-NOAstraZeneca AB176
进行中（未招募）
不适用
A randomised Phase II Study comparing anastrozole and fulvestrant to anastrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21EUCTR2005-005715-22-DEAstraZeneca AB176
已完成
2 期
A randomized controlled study comparing Anastrozole+TS-1 as postoperative chemotherapy in ER positive metastatic breast cancerBreast CancerJPRN-UMIN000000795Department of Breast and Thyroid Surgery, Kawasaki Medical School100